The estimated Net Worth of Mani Mohindru is at least $231 Thousand dollars as of 2 December 2019. Mani Mohindru owns over 4,755 units of Cardiff Oncology stock worth over $40,289 and over the last 9 years Mani sold CRDF stock worth over $190,937.
Sign up
Mani Mohindru CRDF stock SEC Form 4 insiders trading
Mani has made over 7 trades of the Cardiff Oncology stock since 2018, according to the Form 4 filled with the SEC. Most recently Mani sold 4,755 units of CRDF stock worth $81,073 on 2 December 2019.
The largest trade Mani's ever made was exercising 37,431 units of Cardiff Oncology stock on 15 July 2019 worth over $526,280. On average, Mani trades about 4,423 units every 19 days since 2016. As of 2 December 2019 Mani still owns at least 17,441 units of Cardiff Oncology stock.
You can see the complete history of Mani Mohindru stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Mani Mohindru's mailing address?
Mani's mailing address filed with the SEC is 11055 FLINTKOTE AVENUE, C/O CARDIFF ONCOLOGY, INC., SAN DIEGO, CA, 92121.
Insiders trading at Cardiff Oncology
Over the last 5 years, insiders at Cardiff Oncology have traded over $0 worth of Cardiff Oncology stock and bought 966,810 units worth $1,962,891 . The most active insiders traders include Gary W Pace, Gary S Jacob, and Mark Erlander. On average, Cardiff Oncology executives and independent directors trade stock every 41 days with the average trade being worth of $74,449. The most recent stock trade was executed by Gary W Pace on 19 December 2023, trading 30,000 units of CRDF stock currently worth $41,100.
What does Cardiff Oncology do?
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics;CY140, an inhibitor of PLK1, PLK2 and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials;TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
What does Cardiff Oncology's logo look like?
Complete history of Mani Mohindru stock trades at Cara Therapeutics Inc, Curis Inc, CytomX Therapeutics Inc, and Cardiff Oncology
Cardiff Oncology executives and stock owners
Cardiff Oncology executives and other stock owners filed with the SEC include:
-
Dr. Mark Erlander,
CEO & Director -
Charles Monahan R.Ph.,
Sr. VP of Regulatory Affairs -
Dr. Tod Smeal Ph.D.,
Chief Scientific Officer? -
Dr. Katherine L. Ruffner M.D.,
Chief Medical Officer -
James E. Levine,
Chief Financial Officer -
Elizabeth Anderson,
VP of Fin. & Admin. -
Vicki Kelemen,
Exec. VP & COO -
Brigitte Lindsay,
VP of Fin. -
Lale White,
Director -
James O Armitage,
Director -
Gary W Pace,
Director -
Thomas Phd Adams,
-
Rodney S Markin,
Director -
Vicki Kelemen,
Exec. VP and COO -
Mark Erlander,
Chief Executive Officer -
Renee P Tannenbaum,
Director -
Gary S Jacob,
-
James E. Levine,
Chief Financial Officer -
Katherine L Ruffner,
Chief Medical Officer -
John P Brancaccio,
-
Tod Smeal,
Chief Scientific Officer -
Fairooz Kabbinavar,
Chief Medical Officer